Bioxodes

✨ PRESS RELEASE ✨ Bioxodes shows breakthrough potential of innovative therapeutic candidate BIOX-101 for stroke with encouraging Phase 2a data from patients with intracerebral hemorrhage. The results – announced today - confirm the positive findings of the first set of interim results from the trial, released in April. “These results suggest BIOX-101 may become a disruptive novel therapeutic, offering a long-awaited breakthrough for treatment of stroke, starting with ICH,” said Marc Dechamps, CEO of Bioxodes. Here are the highlights of the press release: 🔺 Safety endpoint met, encouraging signs of efficacy; 🔺 Findings suggest BIOX-101 reduced hematoma volume and slowed perihematomal edema growth; 🔺Trend to functional recovery with BIOX-101 more favorable than in standard-of-care group; 🔺Consistent anti-inflammatory biomarker responses aligned with positive clinical efficacy signals; 🔺No deaths after a mean follow-up of 8 months. The Data Monitoring Committee in its recommendation unanimously endorsed proceeding to a Phase 2b or Phase 3 efficacy trial. Bioxodes is currently raising a Series B financing to fund a potentially registrational Phase 2b clinical trial. 👉 full press release link in the comments 👇 #stroke #biotech #voiceofstroke #innovation #biox101 #clinicaltrial

💡 Ischemic vs. hemorrhagic stroke: the difference everyone should know. 🧠 Knowing more about stroke can save lives. For instance, knowing that there are two types of stroke, which are very different. 🔵 Ischemic stroke is caused by a blood clot in a blood vessel. It’s by far the most common type of stroke. In some cases, doctors can treat it with blood thinners. 🔴 Intracerebral hemorrhage (ICH) is much rarer: only around 15% of all cases. But its statistics are grim: half of the patients die within 30 days. And there are no drugs to treat it. At Bioxodes, we're developing a first-in-class drug to treat ICH. Want to know more? Have a look at bioxodes.com #HealthEducation #MedicalEmergency #voiceofstroke #bioxodes #BIOX101

🧠 What is ICH and why it matters: Most people have heard of stroke. You may even know somebody who suffered one. But if you zoom in on the word, you’ll find there are several diseases that are all called stroke. One is intracerebral hemorrhage (ICH). It’s a particularly deadly condition. While it accounts for only 10 to 20% of all strokes, it is behind 40% of all stroke-related deaths. At Bioxodes, we are developing drugs to treat ICH. And we want to raise awareness for it. Because awareness drives action, such as early diagnosis and critical care. Both can be life savers. Bioxodes. Offering a breakthrough hope for stroke patients.   #StrokeAwareness #HealthcareInnovation #voiceofstroke

🤔 Did You Know? #DYK? That neutrophils, a type of white blood cell, play a complex role in stroke recovery? At Bioxodes, we're exploring how these cells contribute to both brain damage and repair, aiming to develop innovative treatments that target these processes. 🧠 Our work focuses on harnessing the potential of neutrophils to improve outcomes for stroke patients. 🩸🧫 Check out our website for more insights www.bioxodes.com #ImmuneSystem #StrokeTreatment #Bioxodes #biotech #StrokeAwareness

✨ Another press hit for Bioxodes! The #InVivo magazine (Citeline) for pharma pros took a deep dive into Bioxodes, highlighting everything from our science to our plans for BIOX-101 - a revolutionary new treatment in development for intraceberal hemorrhage, an often deadly type of stroke. BIOX-101 is derived from the saliva of the tick, a discovery stemming from decades of research at the Free University of Brussels (ULB), CEO Marc Dechamps explained. The first-in-class drug candidate exerts both anti-inflammatory and anti-clotting effects, yet – crucially - without increasing the risk of bleeding. The article also laid out our plans to bring BIOX-101 to market as we start to prepare for the launch of a potentially registrational trial in early 2027. To read more about our science, go to www.bioxodes.com 🌐 👉 To read the article, click on this link (subscription required): https://lnkd.in/em6yWjYf #voiceofstroke #strokecare #bioxodes #BIOX101 #biotech #clinicaltrial

Bioxodes has ambitious plans to bring BIOX-101 to treat hemorrhagic stroke to market – which CEO Marc Dechamps unfolded in an interview with Mergermarket. Highlights of the article by Anastasia Gnezditskaia were: ➡️ Bioxodes plans €70 million Series B funding round to be completed by the end of this year or early 2026 ➡️ Goal of the funding round is to complete clinical trials for BIOX-101 and bring the therapeutic candidate to market ➡️ Bioxodes has mandated KBC Securities to run the capital raise ➡️ Company is tentatively planning an exit sale to a preferably global pharma player, or a regional one, preferably Asian BIOX-101 is a first-in-class drug candidate designed to prevent the devastating secondary effects of a hemorrhagic stroke, targeting thrombo-inflammation at its source. To read more about our science, please go to www.bioxodes.com #voiceofstroke #strokecare #bioxodes #BIOX101 #biotech #clinicaltrial

🧠 Did you know that brain bleeds or Intracerebral hemorrhage (ICH)  cause nearly half of all stroke deaths, yet most people have never heard of intracerebral hemorrhage (ICH)? That’s why Marc Dechamps calls for greater awareness in hospitals and beyond  in a guest contribution in Clinical Leader, a widely read magazine. “Delays in treating patients are often compounded in hospitals that are insufficiently prepared to deal with stroke… even the initial diagnosis of [intracerebral hemorrhage] can be delayed,” he explains. The lack of an effective therapy is making that situation even more acute. Bioxodes is developing BIOX-101, the first potential treatment designed to tackle both inflammation and clotting, without increasing bleeding risk. 🔬 We’ve just seen promising results from our Phase 2a trial—and are preparing a Phase 2b study, expected to launch in early 2027, which could be a game-changer for patients 💡 Curious to learn more? Read the full article in Clinical Leader 👉 https://lnkd.in/eU8cc6sQ 🙏 Abby Proch, Clinical Leader #voiceofstroke #strokecare #bioxodes #BIOX101 #biotech #clinicaltrial

🎉 Thank you, BioWin, for sharing the Bioxodes story! None of what we have achieved would have been possible without the dedication and resilience of our incredible team and the unwavering support of our investors. Together, we've made tremendous strides in developing innovative therapies like BIOX-101, bringing us closer to transforming stroke care. 🙌 Special thanks to: SFPIM, Sambrinvest Financière Spin-off luxembourgeoise, #LSRP Marc Dechamps, Stéphanie Demoulin, Charlotte Corbisier, Cindy Hespel, Hans Warrinnier, Valérie Pireaux, Sandrine Derochette, Bioxodes 📖 Dive into the full article to learn more about our journey and breakthroughs. 👇 #BioxodesTeam #InnovationInHealth #CollaborativeSuccess

🌟 Only good vibes at the Belgian Pavillon, booth #2135! Did you see our poster yet highlighting Bioxodes' key information? Discover BIOX-101, a potential game-changer for Intracerebral Hemorrhage (ICH) treatment, addressing a significant unmet medical need and aiming to become the new standard of care. 🧠 🔻 Tackles 40% of stroke-related deaths and life-threatening complications. 🔻 Fast track to market with high-value potential and a concentrated target in US-EU stroke units and ICUs. 🔻 Aiming for $1.5 billion in annual sales with realistic assumptions and targeted geography. Our innovation could expand to other forms of stroke, offering hope and improved outcomes. Interested in learning more about how we're revolutionizing ICH treatment? 🤔 Check out our poster below and head over to our website for more info: bioxodes.com Marc Dechamps, BIO International Convention Wallonia Export & Investment Agency (AWEX), FIT - Flanders Investment & Trade #voiceofstroke #strokecare #bioxodes #BIOX101 #belgianpavillon #BIO2025

🔻 Exciting News from BIO Boston! 🔺 Our journey at the BIO International Convention in Boston kicked off yesterday, June 12th, with the K-BioX Global Summit 2025. This remarkable event was hosted by the City of Chuncheon, KAMC, Rutgers University, and K-BioX. We were honored to be the sole industry representative at the summit, sharing insights on Bioxodes' latest developments. The sessions were incredibly engaging, featuring attendees from Korea and the US, spanning government, academia, and industry sectors. A huge thank you to Wallonia Export & Investment Agency (AWEX) and BioWin for your invaluable support and this incredible opportunity! 🙏 Marc Dechamps, Mehdy Oozeer, Frédéric Tonglet, Benjamin DAMIEN #BIO2025 #Korea #GlobalSummit #BioInternationalConvention